about
An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic DrugsFailure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.Therapeutic Drug Monitoring of the Newer Anti-Epilepsy MedicationsClinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.A mechanistic approach to antiepileptic drug interactions.Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.Effects of vigabatrin, an irreversible GABA transaminase inhibitor, on ethanol reinforcement and ethanol discriminative stimuli in mice.A Novel Strategy for Attenuating Opioid Withdrawal in Neonates.Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.Vigabatrin for infantile spasms.Treatment options for refractory and difficult to treat seizures: focus on vigabatrinPharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.Pharmacokinetic interaction studies between felbamate and vigabatrin.Vigabatrin (Sabril), a Gamma-Aminobutyric Acid Transaminase Inhibitor for the Treatment of Two Catastrophic Seizure Disorders.Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats.Antiepileptic drugs and pregnancy outcomes.
P2860
Q28069989-A2F69E89-FFCA-4441-8356-0516160FDE4AQ33723355-093272E2-792E-409F-A7C7-AC031C590948Q33996679-2396576C-37FB-424A-89DD-22C72F4B0A95Q34342674-19F92462-D4E4-4235-9287-036803649305Q34469990-03AB1C2C-E9B5-4128-88C0-526D9456188AQ34570859-A68BFAB1-05A8-4CD5-A08A-B2CBD9221716Q35014028-5C78E125-DAC2-45A2-B1FB-039EAD5B5EF7Q35812640-C102E7E3-90C9-40C8-ABB7-143A4D4D1B92Q37574445-206DB456-C287-478B-B939-8AB3B1877E0FQ37642768-932A9E78-2769-4B8F-8B61-2070BAFB1C0FQ37848404-EAE441E8-7DF2-4CEF-B8BC-39236617ADE0Q37937441-70BD75DA-0BDC-4917-850D-360267AD51B8Q38152329-3D318E4D-5522-464C-89E7-F630A13DB33CQ38261962-C56E0EC6-F533-4EAA-AD24-1C3A6D7B4D01Q43201999-A12FB79E-687B-4340-8FEA-54C6EB18746AQ46432146-DC095B8C-71DD-4052-B32F-C0B822E4F0DAQ48657505-9DF33D12-E3E6-45C2-877D-2E8BBE26A65CQ55716842-8E108C2F-6A21-4616-B863-0493600475A7
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Vigabatrin. Clinical pharmacokinetics.
@ast
Vigabatrin. Clinical pharmacokinetics.
@en
type
label
Vigabatrin. Clinical pharmacokinetics.
@ast
Vigabatrin. Clinical pharmacokinetics.
@en
prefLabel
Vigabatrin. Clinical pharmacokinetics.
@ast
Vigabatrin. Clinical pharmacokinetics.
@en
P2093
P1476
Vigabatrin. Clinical pharmacokinetics.
@en
P2093
P304
P356
10.2165/00003088-199223040-00003
P577
1992-10-01T00:00:00Z
P6179
1029075877